Search Results
Your search for ,maY matches 16890 pages
Showing 9351 - 9400FDA Expands Approval of Blinatumomab for Certain Patients With B-Cell Precursor ALL
The U.S. Food and Drug Administration granted accelerated approval to blinatumomab (Blincyto) to treat adults and children with B-cell precursor acute lymphoblastic leukemia (ALL) who are in remission but still have minimal residual disease (MRD). In patients who have achieved remission after...
Study Cites Geographic Disparities in Lung Cancer Mortality Rates Among Women
According to the American Cancer Society, lung cancer is the leading cause of death among men and women, killing about 84,000 men and 71,000 women each year. Although lung cancer–related death rates in the United States have declined steadily since 1990 in men, they did not start to decline...
SGO 2018: New Data Suggest Cervical Cancer Age-Based Screening Guidelines Should Be Reconsidered
One in five women diagnosed with cervical cancer in the United States will be diagnosed after the age of 65, suggesting that the recommended age to stop cervical cancer screening should be reconsidered, according to research presented at the Society of Gynecologic Oncology’s (SGO) 2018 Annual ...
EBCC-11: Double Mastectomy in BRCA1 and BRCA2 Carriers
Healthy women who carry a breast cancer–causing mutation in the BRCA1 gene not only reduce their risk of developing the disease but also their chances of dying from it if they have both breasts removed, according to new research presented at the 11th European Breast Cancer Conference...
FDA Grants Breakthrough Therapy Designation to Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
On March 26, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to enfortumab vedotin, an antibody-drug conjugate (ADC), for patients with locally advanced or metastatic urothelial cancer who were previously treated with checkpoint inhibitors. Breakthrough Therapy ...
SGO 2018: Gender Differences May Play a Role in Lack of HPV Vaccination
Parents are less likely to vaccinate adolescent boys than girls with the human papillomavirus (HPV) vaccine, and they are twice as likely to report their main reason as a lack of provider recommendation, according to a study presented at the 2018 Society of Gynecologic Oncology (SGO) Annual Meeting ...
Outcomes With a Payer-Sponsored Medicare Advantage Cancer Management Program
In a study reported in the Journal of Oncology Practice, Hoverman et al found that a Texas Oncology–Aetna Medicare Advantage collaboration resulted in cost savings, good adherence to treatment pathways, and high patient satisfaction over 3 years. Study Details The collaborative...
SGO 2018: PARP-7 Protein May Play a Significant Role in Survival for Ovarian Cancer
Patients with ovarian cancer with genetic amplification in the PARP-7 protein survived longer than those without the mutation, according to a presentation at the Society of Gynecologic Oncology’s (SGO) 2018 Annual Meeting on Women’s Cancer. These results call for researchers to further...
EBCC-11: Risk of a Second Breast Cancer Can Be Better Quantified in Patients With a BRCA Mutation
The risk of a second breast cancer in patients with high-risk BRCA gene mutations can be more precisely predicted by testing for several other genetic variants, each of which are known to have a small impact on breast cancer risk, according to new research presented at the 11th European Breast...
Genomic Copy Number Aberrations and Extremely Poor Survival in High-Risk Neuroblastoma
In a study reported in the Journal of the National Cancer Institute, Depuydt et al identified two genomic copy number aberrations associated with risk of extremely poor survival in patients with high-risk neuroblastoma. Study Details The international collaborative study included normalized...
Bijal D. Shah, MD, on What ALL Tells Us About CAR T Cells
Bijal D. Shah, MD, of the H. Lee Moffitt Cancer Center, discusses key studies of CAR T-cell therapy in relapsed B-cell ALL and the adverse events that this treatment may cause.
When Is Active Surveillance Appropriate in the Treatment of DCIS?
In 2017, more than 63,000 women in the United States were diagnosed with in situ breast cancer. The overwhelming majority of those women, about 83%, were diagnosed with ductal carcinoma in situ (DCIS), a condition characterized by the presence of abnormal cells confined to the breast milk ducts;...
Duration of Adjuvant Oxaliplatin-Based Therapy for Stage III Colon Cancer
“At Microphone 1” is an occasional column written by Steven E. Vogl, MD, of the Bronx, New York. When he is not in his clinic, he can generally be found at major oncology meetings and often at the microphone, where he stands ready with critical questions for presenters of new data. The opinions...
Long-Term Risk of Cardiovascular Disease Increased Among Colorectal Cancer Survivors
COMPARED TO the general population, the risk of cardiovascular disease among colorectal cancer survivors was significantly increased more than 10 years after their cancer diagnosis, according to research presented by David Baraghoshi, MSTAT candidate, of the Huntsman Cancer Institute at the...
Raising Awareness of the Link Between Alcohol and Cancer
Prevention in Oncology is guest edited by Jennifer Ligibel, MD, Chair of ASCO’s Energy Balance Working Group and a member of ASCO’s Cancer Survivorship and Cancer Prevention Committees. Dr. Ligibel is Director of the Leonard P. Zakim Center for Integrative Therapies at Dana-Farber Cancer...
Gut Bacteria May Determine Speed of Tumor Growth in Pancreatic Cancer
The population of bacteria in the pancreas increases more than a thousandfold in patients with pancreatic cancer and becomes dominated by species that prevent the immune system from attacking tumor cells. These are the findings of an early study conducted on pancreatic ductal adenocarcinoma,...
Fruquintinib in Pretreated Advanced NSCLC
In a Chinese phase II trial reported in the Journal of Clinical Oncology, Lu et al found that the VEGFR-1,-2, and-3 kinase inhibitor fruquintinib was active in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) who progressed after two prior chemotherapy regimens. Study Details ...
EAU 2018: Prostate MRI Reveals More Clinically Significant Cancers, Reduces Overdiagnosis Compared to Standard Biopsy
A large international study has shown that magnetic resonance imaging (MRI) can reduce the number of invasive prostate biopsies by up to 28%. The PRECISION trial showed that using MRI to target prostate biopsies leads to more harmful and fewer harmless prostate cancers being diagnosed. The results...
EAU 2018: Study Finds a Quarter of Penile Cancer Patients Do Not Receive Recommended Treatment
A major international survey has found that around a quarter of patients with penile cancer are not receiving the recommended treatment, and that these patients had half the survival rate of those who were treated according to guidelines. The study, presented at the European Association of Urology...
EAU 2018: Survey Shows Greater Suicide Rate in Patients With Urologic Cancers
A major UK survey has shown that patients with urologic cancer—such as prostate, bladder, or kidney cancer—are five times more likely to commit suicide than people without cancer. The analysis also shows that patients with cancer generally are around three times more likely to commit...
FDA Grants Priority Review to sNDA for Enzalutamide in Nonmetastatic Castration-Resistant Prostate Cancer
On March 19, a supplemental New Drug Application (sNDA) for enzalutamide (Xtandi) was accepted for filing and granted Priority Review designation by the U.S. Food and Drug Administration (FDA). If approved, the sNDA would expand the indication of enzalutamide to include men with nonmetastatic...
New NCCN Guidelines Aim to Encourage More People Living With HIV and Cancer to Receive Appropriate Cancer Treatment
The National Comprehensive Cancer Network® (NCCN) has released new NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) intended to help make sure people living with human immunodeficiency virus (HIV) who are diagnosed with cancer receive safe, necessary treatment. According to a...
Ashwagandha
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Gary Deng, MD, PhD, and Jyothirmai Gubili, MS, present information on...
Impact of Lifestyle Choices on Outcomes in Survivors of Gastrointestinal Cancers
Physical inactivity among adult survivors of gastrointestinal cancers was tied to poor health-related quality of life, according to researchers at the American Psychosocial Oncology Society (APOS) Annual Meeting.1 Also, physical inactivity (Chi-square = 5.605, P = .018) and alcohol use (Chi-square ...
Triplet Therapy Poses a Triple Threat to BRAF-Mutated Colorectal Cancers
Triplet therapy that inhibits the BRAF, MEK, and epidermal growth factor receptor (EGFR) pathways appears promising in BRAF-mutated colorectal cancer, a malignancy that typically does not respond to BRAF inhibition alone. Early results from the BEACON CRC study showed a 48% response rate and an...
Studies Explore Colon Tumor Sidedness, Lung Radiation Dose in Esophageal Cancer, Pembrolizumab in Liver Cancer, and More
Along with full coverage of key presentations from the 2018 Gastrointestinal Cancers Symposium, The ASCO Post brings our readers this additional news roundup. Side Matters in Colon Cancer One of the studies included in the global IDEA trial, which compared 3 vs 6 months of adjuvant chemotherapy in ...
Trivalent CAR T-Cell Design May Enhance Antitumor Efficacy in Acute Lymphoblastic Leukemia
A novel approach to chimeric antigen receptor (CAR) T-cell therapy seems to effectively target acute lymphoblastic leukemia (ALL) cells with varying antigen profiles and may help to overcome antigen escape, seen with CD19-targeted therapy. According to data presented at the 2018 ASCO-SITC Clinical...
Testicular Cancer Survivors and Adequate Screening for Long-Term Heart Disease
Testicular cancer is the most common cancer in young men. The majority of patients are cured of their disease, but a newly published study shows many remain at risk for later complications from chemotherapy or other treatments. The study, published by Zaid et al in JNCCN –Journal of the...
ASTRO Issues New Clinical Guideline for Whole-Breast Radiation Therapy
The American Society for Radiation Oncology (ASTRO) has issued a new clinical guideline for the use of whole-breast radiation therapy for breast cancer that expands the population of patients recommended to receive hypofractionated treatment. The guideline was published by Smith et al in...
Expert Point of View: Ravindra Uppaluri, MD, PhD
Discussant of the abstract, Ravindra Uppaluri, MD, PhD, Chief of the Division of Otolaryngology in the Department of Surgery at the Brigham and Women’s Hospital and Director of Head and Neck Surgical Oncology at the Dana-Farber Cancer Institute, said this research underscores the complex biology...
Testing for PD-L1 Amplification May Help Predict Response to Immune Checkpoint Blockade in Solid Tumors
Analysis of more than 100,000 patients with cancer for gene CD274 (programmed cell death ligand 1 [PD-L1]) amplification may have implications for treatment with immune checkpoint blockade. Although shown to be rare in solid tumors, copy number alterations in PD-L1 genes were present in more than...
Expert Point of View: Ezra Cohen, MD, PhD
Discussant for the abstract, Ezra Cohen, MD, PhD, of the University of California, San Diego, pointed out that although this subgroup may be responsive to checkpoint inhibition, it may not necessarily be anti–programmed cell death protein 1 (anti–PD-1) therapy. “There are emerging data suggesting...
Targetable Immune Biology Found in Some Patients With Early-Stage Prostate Cancer
Although immunotherapy has improved outcomes across a growing number of cancers, its success in unselected cases of prostate cancer has been limited. According to data presented at the 2018 ASCO-SITC Clinical Immuno-Oncology Symposium, however, investigators have identified a group of patients with ...
Treatment Trends for Lymph Node–Positive Penile Cancer
In a study of data from the National Cancer Database reported in JAMA Oncology, Joshi et al found that two-thirds of patients with node-positive nonmetastatic squamous cell carcinoma of the penis received lymph node dissection and approximately half received chemotherapy in recent years. ...
Small Study Evaluates Novel Combination in Metastatic Prostate Cancer
The combination of the poly ADP-ribose polymerase (PARP) inhibitor olaparib (Lynparza) and the programmed cell death ligand 1 (PD-L1) inhibitor durvalumab (Imfinzi) produced positive preliminary results in men with metastatic, castration-resistant prostate cancer previously treated with...
Why Right-to-Try Laws Are Dangerous
Why wouldn’t you support a patient with a terminal illness the “right to try” any therapy that may save his or her life? The answer to this question—one engulfed in a political debate in Congress—seems simple. It is not. [Editor’s Note: [Editor’s Note: On May 30, 2018, the President signed into...
Poorer Socioeconomic Status May Predict Lower Survival in Patients With Anal Cancer
Patients with lower income have a significantly reduced chance of surviving anal cancer, according to a new study led by investigators at NYU Langone Health’s Perlmutter Cancer Center published by Lin et al in the journal Cancer. The study shows that both overall and...
Expert Point of View: Francis P. Worden, MD
The moderator of the session, Francis P. Worden, MD, a medical oncologist at the University of Michigan Health System Comprehensive Cancer Center, in Ann Arbor, highlighted the number of poorly differentiated carcinomas, which is higher than reported in other previous, large studies. “In previous...
Cabozantinib Therapy Shows Activity in Differentiated Thyroid Cancer
Cabozantinib (Cometriq) has demonstrated significant activity in the first-line setting for radioiodine-refractory differentiated thyroid carcinoma, according to data from a single-site phase II trial presented at the 2018 Multidisciplinary Head and Neck Cancers Symposium.1 Treatment with...
FDA Grants Breakthrough Therapy Designation to Erdafitinib for the Treatment of Metastatic Urothelial Cancer
On March 15, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to erdafitinib for the treatment of urothelial cancer. Urothelial cancer, most frequently in the bladder, is the sixth most common type of cancer in the United States. A Breakthrough Therapy ...
MRI-Based Model for Prostate Biopsy Risk Stratification
In a study reported in JAMA Oncology, Mehralivand et al found that inclusion of magnetic resonance imaging (MRI) findings in a predictive model may reduce unnecessary biopsies in men with suspected prostate cancer. Study Details In the study, a predictive model adding MRI-derived prostate volume...
AACR 2018: Acquired HER2 Mutations Confer Resistance to Hormone Therapy in ER-Positive Metastatic Breast Cancer
Mutations in HER2 were found to confer resistance to hormone therapy in some estrogen receptor (ER)-positive metastatic breast cancer cases, and resistance could be reversed by dual treatment with the hormone therapy fulvestrant (Faslodex) and the HER2 kinase inhibitor neratinib (Nerlynx),...
AACR 2018: Prior Chemotherapies May Impair Pediatric Patients’ Ability to Develop Effective CAR T Cells
Pediatric patients with solid tumors may have poor quality T cells compared to patients with leukemia, and certain chemotherapies were detrimental to the T cells and their potential to become chimeric antigen receptor (CAR) T cells, according to data presented during a media preview for the...
AACR 2018: Chlamydia Infection May Be Associated With Increased Risk of Ovarian Cancer
An antibody that is present in the blood of women previously infected with the sexually transmitted infection chlamydia is associated with a doubling in ovarian cancer risk, according to data presented during a media preview for the 2018 American Association for Cancer Research (AACR) Annual...
AACR 2018: Underserved Populations Lack Information About Clinical Trials, Biobanking
People in Louisiana communities with cancer health disparities would be interested in participating in clinical trials or submitting samples to biobanks if provided information about these opportunities by a trusted physician—but physicians reported lacking appropriate information to give to...
Association of Early Palliative Care With Patient-Reported Outcomes and End-of-Life Care
In a study reported in the Journal of Clinical Oncology, Hoerger et al found that patients with a higher proportion of early palliative care visits addressing behavioral coping strategies had improvement in depression symptoms and quality of life. In addition, those with a high proportion of visits ...
Radioembolization vs Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma
In an investigator-initiated phase III SIRveNIB trial in Asia-Pacific patients reported in the Journal of Clinical Oncology, Chow et al found no difference in overall survival with selective internal radiation therapy, or radioembolization, vs sorafenib (Nexavar) in patients with unresectable...
Many AYA Cancer Survivors Have More Social Connections Than Peers With No History of Cancer
Survivors of adolescent and young adult (AYA) cancer often have stronger social networks than their peers with no cancer history, according to St. Jude Children’s Research Hospital researchers, who hope to translate that support into better health outcomes for the nation’s...
Patients With AML Have Reduced Risk of Early Mortality at NCI-Designated Cancer Centers
Researchers at the University of California (UC), Davis, have shown that patients with acute myeloid leukemia (AML) who received their care at a National Cancer Institute (NCI) cancer center in California had a dramatically reduced risk of early mortality. Using data from the California Cancer...
CAR T-Cell Therapy in Refractory B-Cell Lymphomas
As reported at the 2017 American Society of Hematology Annual Meeting & Exposition and in The New England Journal of Medicine, Stephen J. Schuster, MD, of the Perelman School of Medicine at the University of Pennsylvania, and colleagues found that chimeric antigen receptor (CAR) T-cell...
